You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生/四環/泰凌跌5%-15% 麗珠醫藥隨A股續升逾5%
阿思達克 12-24 14:05
中金日前報告指,內地注射劑新藥審評提速,第三輪集採政策近期有望正式落地。醫藥股今天以生產疫苗泰凌醫藥(01011.HK)表現最差,股價挫15%半日收0.155元,再度逼近上周二盤中所創上市低位0.14元,半日成交急增至4,025萬股。三生製藥(01530.HK)也續跌5%半日收9.82元,創逾11個月低,半日成交增至1,013萬股。四環醫藥(00460.HK)回吐5%半日收0.95元,股價失守50天線(0.99元),半日成交增至1,603萬股。 相反,麗珠醫藥(01513.HK)續升5.3%半日收23.85元;其A股高見32.98元人民幣,現造32.8元,升5.4%。威高股份(01066.HK)續升2.9%半日收9.1元,股價重越10天線(8.94元)。 中金12月22日報告指,截至目前止,中國藥監局已對16個注射劑品種批出企業通過或視同通過一致性評價,注射劑新藥審批速度有所加快,意味後續納入集中採購注射劑品種將逐步提升,預計第三批集採有望近期正式落地,推進速度加快。新一輪集採或將引入多個新規則,競爭可能進一步加劇。政策密集推出對板塊估值產生較大影響,注射劑一致性評價推進及後續加快集採納入可能對上市公司業績帶來一定不確定性。(sz/u)~ 阿思達克財經新聞 網址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account